International Conference on Dupuytren Disease and Related Disorders Groningen, The Netherlands Day 1 Friday, 22 May 15 08:00 08:30 08:35 08:40 08:45 09:05 Registration Welcome Paul Werker Jos Aartsen CEO UMCG Wolfgang Wach & Charles Eaton Lecture : Treatment of Dupuytren in Zolt Szabo Chair : Paul different countries and the role of FESSH Werker and IFSSH in promoting knowledge for hand surgeons Session 1: Epidemiology & Patients Views Chair : Bert Reichert & Zsolt Szabo 09:05 The epidemiology of surgical intervention Joe Dias for Dupuytren's Contracture in England 09:11 Favorite Options of German Hand Surgeons Bert Reichert in the Treatment of Dupuytren Disease 09:17 Trends in Dupuytren’s Treatment in the United States Discussion The Patient’s View and Needs – An International Survey: Dupuytren Disease Patients’ preferences for treatment for Dupuytren’s disease: a Discrete Choice Experiment Discussion Coffee Break Lecture : The extra-‐cellular matrix in Dupuytren's disease 09:23 09:38 09:44 09:50 10:00 10:30 10:50 10:50 10:56 11:02 11:08 Session 2: Cellular and extracellular events PDGFR-‐β targeted modified interferon gamma in Dupuytren’s disease Wnt pathway in Dupuytren disease, connecting pro-‐fibrotic signals Biomarkers of post-‐surgical outcome in Dupuytren’s disease Tumour necrosis factor (TNF) as a therapeutic target in Dupuytren’s disease Philip Blazar Wolfgang Wach Hester Kan David O'Gorman Chair : Boris Hinz & Ruud Bank Chair : Boris Hinz & Ruud Bank Marianna Kruithof-‐de Julio Marike van Beuge Ian Clark Jagdeep Nanchahal 11:14 11:30 11:32 11:37 11:42 12:00 13:00 13:20 13:20 13:26 13:32 13:38 13:53 13:59 14:05 14:15 14:17 14:22 14:27 14:45 15:15 15:35 15:35 Discussion Controversies 1: Pathogenesis of Dupuytren Disease; active or passive contracture? Active Contracture Passive Contracture Audience response Lunch Lecture : Genetics in Dupuytren Disease Chair : David O'Gorman Jagdeep Nanchahal Charles Eaton Roel Ophoff Chair : Hans Hennies Chair : Roel Ophoff & Hans Hennies Michael Ng Session 3: Genetics & Associations A Large European Genome-‐wide Association Study Reveals Multiple New Genetic Susceptibility Variants for Dupuytren's Disease Meta-‐analysis of genome-‐wide imputed Kerstin Becker GWAS identifies new significant loci in patients with Dupuytren´s disease Identification and characterization of Juanjiangmeng Du functional genetic variants in Dupuytren’s Disease Discussion A systematic review and meta-‐analysis on Dieuwke Broekstra the association between Dupuytren disease and diabetes The association between vibration and Dieuwke Broekstra Dupuytren disease: a comparison between elderly field hockey players and controls Discussion Controversies 2: The benefit of splinting for Chair : Ilse Degreef Dupuytren Contracture Splinting confers no benefit Adrian Chojnowski Splinting is beneficial Wolfgang Wach Audience response Coffee Break Lecture : Collagenase Treatment - Larry Hurst Journey from Bench to Current Advanced Clinical Use Chair : Steve Coleman & Stephan Wilbrand Session 4: Collagenase Injection Chair : Steve Coleman & Stephan Wilbrand Dupuytren's Disease in the thumb and first Paul Werker webspace and collagenase treatment 15:41 15:47 15:53 15:59 16:19 16:24 16:30 16:36 16:42 16:48 Efficacy of using local anesthesia before Jesper Nordenskjöld collagenase injection in reducing overall pain experience in patients treated for Dupuytren’s contracture: A quasi-‐ randomized study Effect of Delayed Finger Extension on the Gary M. Pess Efficacy and Safety of Collagenase Clostridium Histolyticum Treatment for Dupuytren’s Contracture The use of a dynamic dorsal splint for Massimo Corain Dupuytren Rehabilitation after collagenase Discussion Dupuytren Award 2014 Wolfgang Wach & Paul Werker Treatment with Collagenase Clostridium Clayton A. Peimer Histolyticum: Five-‐Year CORDLESS Data Prospective Multicenter, Multinational Marie Badalamente Study to Evaluate the Safety and Efficacy of Concurrent Collagenase Clostridium Histolyticum Injections to Treat Two Dupuytren’s Contractures in the Same Hand An Open-‐label, Controlled Phase 2a Study Marie Badalamente of the Safety and Efficacy of Injectable Collagenase Clostridium Histolyticum (CCH) in Patients with Adhesive Capsulitis (Frozen Shoulder) Collagenase-‐ what we may never know-‐ a David Warwick discussion paper Discussion 17:04 17:06 17:11 17:16 17:34 Controversies 3: The best minimally Chair : Charles Eaton invasive treatment for Dupuytren Disease: PNF or Collagenase? Percutaneous Needle Fasciotomy Paul Werker Collagenase David Warwick Audience Response Day 2 Saturday, 23 May 15 08:00 08:30 08:30 08:36 08:42 08:48 09:03 09:09 09:15 09:21 09:37 09:41 09:46 09:51 10:15 Registration Session 5: Assessment/ Percutaneous Needle Fasciotomy MCID for the Patient Evaluation Measure as a Patient Rated Outcome Measure for Dupuytren Contracture Predictors of Satisfaction with Hand Function in Patients with Dupuytren’s Disease URAMS as a PROM for Dupuytren Contracture Patients Discussion Tips and Pearls for Percutaneous Needle Fasciotomy and Collagenase -‐ A Ten Year Personal Experience Percutaneous Needle Fasciotomy for secondary or higher recurrence in Dupuytren’s disease Extensive Percutaneous Aponeurotomy and Lipofilling versus Limited Fasciectomy in Patients with Primary Dupuytren’s Contracture; a Randomized Controlled Trial Discussion Controversies 4: How to treat severe PIP contractures: minimally invasive of surgically? Minimally invasive methods Surgical correction Audience response Coffee Break Chair : Gary Pess & Ulrich Lanz Joe Dias Chao Zhou Joe Dias Gary Pess Margot Vlot Steven Hovius Chair : Joe Dias Clayton Peimer Caroline Leclercq 10:45 Lecture : Treatment of Dupuytren Disease: Where are we now 11:05 Session 6: Comparative Studies/ Chair : Caroline Leclercq & David Elliot Recurrence Steroid injection and needle Paul Binhammer aponeurotomy for Dupuytren disease: long-‐ term follow-‐up of a randomized controlled trial Minimal invasive treatment of Duputren: Eva-‐Maria Baur Collagenase vs. PNF Collagenase Clostridium Histolyticum Chao Zhou versus Partial Fasciectomy for Dupuytren's contracture: Early Outcomes From A Multicenter Propensity-‐Score Matched Study Discussion Actual Indications of Continuous Extension Jane C Messina Technique (TEC) For Severe Dupuytren Disease Preliminary soft-‐tissue distraction versus Atanu Biswas checkrein ligament release after fasciectomy in the treatment of Dupuytren proximal interphalangeal joint contractures 11:05 11:11 11:17 11:23 11:35 11:41 11:47 11:55 12:01 12:07 12:15 12:21 12:27 12:33 12:45 13:45 13:50 Discussion The Palmodigital Spiralling Sheath Clusters in short term disease course in participants with primary Dupuytren Disease Discussion Recurrence after Treatment for Dupuytren’s Disease; A consensus-‐based definition Recurrence after Dupuytren’s disease: the time factor Is Recurrence of Dupuytren Disease Prevented by Full-‐Thickness Grafting Surgery? Discussion Lunch Housekeeping Lecture : Radiotherapy for Early Stage Dupuytren and Ledderhose Disease David Elliot Chair : Caroline Leclercq Rinze Lykele Zwanenburg Rosanne Lanting Ruud Selles Caroline Leclercq Ilse Degreef Heinrich Seegenschmiedt Chair : Richard Shaffer & Ruud Selles 14:10 14:10 14:16 14:22 14:32 14:38 14:44 14:54 15:05 15:35 15:40 16:30 17:20 Session 7: Related disease & Other Treatments A Systematic Review Of Non-‐Surgical Treatments For Early Dupuytren’s Disease The Patient’s View and Needs – An International Survey: Ledderhose Disease Discussion Use of Acellular Dermal Matrix in Dupuytren Disease Tension versus compression on Dupuytren Discussion Lecture : Peyronie's Disease Treatment: The State of the Art Coffee Break Focus on Research: Introduction to the symposia Basic Research: important prerequisites for future studies Clinical Research: international collaboration to execute high powered clinical trials Close Chair : Richard Shaffer & Ruud Selles Catherine Ball Gary Manley Gloria Sue Ilse Degreef Mels van Driel Joe Dias Chair : David O'Gorman Chair : Marie Badalamente Wolfgang Wach, Charles Eaton & Paul Werker 1 2 3 4 5 6 7 8 9 10 11 Posters Elevated cAMP Inhibits both Basal-‐ and Latha Satish PDGF-‐Induced Cell Migration and Contraction in Dupuytren’s Contracture-‐ Derived Fibroblasts Correlation of function with deformity in David Warwick Dupuytren’s Disease-‐ the condition specific Southampton Scoring Scheme outperforms the generic QuickDASH Tonometry as an outcome measure for the Catherine Ball treatment of Dupuytren’s disease Intra-‐ and inter-‐observer agreement on Dieuwke Broekstra diagnosis and measurements of Dupuytren disease severity Variation in range of movement reporting Anna Pratt in Dupuytren’s disease Experience of Treating Patients with Stage Andrey Zhigalo IV Dupuytren Contracture Six Years Experience of Using Needle Andrey Zhigalo Aponeurotomy when Treating Patients with Dupuytren's Disease YAP1 is a driver of myofibroblast Bram Piersma differentiation in normal and Dupuytren’s fibroblasts Clinical Validation of Pharmacoeconomic Rafael Sanjuan Model in Dupuytren Contracture Collagenase versus Fasciectomy in Rafael Sanjuan Dupuytren Dissease: Cost-‐Utility Analysis Origin of Dupuytren’s myofibroblasts in an Sofia Karkampouna ex vivo tissue culture system
© Copyright 2024